Search

Your search keyword '"James, Michelle D."' showing total 14 results
Start Over Author "James, Michelle D."
14 results on '"James, Michelle D."'

1. Supplementary Figure 2 from Somatic Profiling of the Epidermal Growth Factor Receptor Pathway in Tumors from Patients with Advanced Colorectal Cancer Treated with Chemotherapy ± Cetuximab

Author

Smith, Christopher G., primary, Fisher, David, primary, Claes, Bart, primary, Maughan, Timothy S., primary, Idziaszczyk, Shelley, primary, Peuteman, Gilian, primary, Harris, Rebecca, primary, James, Michelle D., primary, Meade, Angela, primary, Jasani, Bharat, primary, Adams, Richard A., primary, Kenny, Sarah, primary, Kaplan, Richard, primary, Lambrechts, Diether, primary, and Cheadle, Jeremy P., primary

Published
2023
Full Text
View/download PDF

2. Supplementary Figure 3 from Somatic Profiling of the Epidermal Growth Factor Receptor Pathway in Tumors from Patients with Advanced Colorectal Cancer Treated with Chemotherapy ± Cetuximab

Author

Smith, Christopher G., primary, Fisher, David, primary, Claes, Bart, primary, Maughan, Timothy S., primary, Idziaszczyk, Shelley, primary, Peuteman, Gilian, primary, Harris, Rebecca, primary, James, Michelle D., primary, Meade, Angela, primary, Jasani, Bharat, primary, Adams, Richard A., primary, Kenny, Sarah, primary, Kaplan, Richard, primary, Lambrechts, Diether, primary, and Cheadle, Jeremy P., primary

Published
2023
Full Text
View/download PDF

3. Supplementary Figure Legends from Somatic Profiling of the Epidermal Growth Factor Receptor Pathway in Tumors from Patients with Advanced Colorectal Cancer Treated with Chemotherapy ± Cetuximab

Author

Smith, Christopher G., primary, Fisher, David, primary, Claes, Bart, primary, Maughan, Timothy S., primary, Idziaszczyk, Shelley, primary, Peuteman, Gilian, primary, Harris, Rebecca, primary, James, Michelle D., primary, Meade, Angela, primary, Jasani, Bharat, primary, Adams, Richard A., primary, Kenny, Sarah, primary, Kaplan, Richard, primary, Lambrechts, Diether, primary, and Cheadle, Jeremy P., primary

Published
2023
Full Text
View/download PDF

4. Supplementary Figure 1 from Somatic Profiling of the Epidermal Growth Factor Receptor Pathway in Tumors from Patients with Advanced Colorectal Cancer Treated with Chemotherapy ± Cetuximab

Author

Smith, Christopher G., primary, Fisher, David, primary, Claes, Bart, primary, Maughan, Timothy S., primary, Idziaszczyk, Shelley, primary, Peuteman, Gilian, primary, Harris, Rebecca, primary, James, Michelle D., primary, Meade, Angela, primary, Jasani, Bharat, primary, Adams, Richard A., primary, Kenny, Sarah, primary, Kaplan, Richard, primary, Lambrechts, Diether, primary, and Cheadle, Jeremy P., primary

Published
2023
Full Text
View/download PDF

5. Supplementary Materials and Methods and Tables 1-5 from Somatic Profiling of the Epidermal Growth Factor Receptor Pathway in Tumors from Patients with Advanced Colorectal Cancer Treated with Chemotherapy ± Cetuximab

Author

Smith, Christopher G., primary, Fisher, David, primary, Claes, Bart, primary, Maughan, Timothy S., primary, Idziaszczyk, Shelley, primary, Peuteman, Gilian, primary, Harris, Rebecca, primary, James, Michelle D., primary, Meade, Angela, primary, Jasani, Bharat, primary, Adams, Richard A., primary, Kenny, Sarah, primary, Kaplan, Richard, primary, Lambrechts, Diether, primary, and Cheadle, Jeremy P., primary

Published
2023
Full Text
View/download PDF

6. Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial

Author

Maughan, Timothy S, Adams, Richard A, Smith, Christopher G, Meade, Angela M, Seymour, Matthew T, Wilson, Richard H, Idziaszczyk, Shelley, Harris, Rebecca, Fisher, David, Kenny, Sarah L, Kay, Edward, Mitchell, Jenna K, Madi, Ayman, Jasani, Bharat, James, Michelle D, Bridgewater, John, Kennedy, M John, Claes, Bart, Lambrechts, Diether, Kaplan, Richard, and Cheadle, Jeremy P

Published
2011
Full Text
View/download PDF

10. Pre-trial inter-laboratory analytical validation of the FOCUS4 personalised therapy trial

Author

Richman, Susan D., Adams, Richard Alexander, Quirke, Phil, Butler, Rachel, Hemmings, Gemma, Chambers, Phil, Roberts, Helen, James, Michelle D., Wozniak, Sue, Bathia, Riya, Pugh, Cheryl, Maughan, Timothy Stanley, and Jasani, Bharat

Subjects
Observer Variation, COLORECTAL CANCER, Laboratory Proficiency Testing, Wales, Biopsy, Patient Selection, DNA Mutational Analysis, Reproducibility of Results, Immunohistochemistry, LABORATORY TESTS, Phenotype, England, Molecular Diagnostic Techniques, Predictive Value of Tests, ANTIBODIES, Mutation, Biomarkers, Tumor, Humans, Original Article, Genetic Predisposition to Disease, Precision Medicine, Colorectal Neoplasms, MOLECULAR PATHOLOGY
Abstract

Introduction Molecular characterisation of tumours is increasing personalisation of cancer therapy, tailored to an individual and their cancer. FOCUS4 is a molecularly stratified clinical trial for patients with advanced colorectal cancer. During an initial 16-week period of standard first-line chemotherapy, tumour tissue will undergo several molecular assays, with the results used for cohort allocation, then randomisation. Laboratories in Leeds and Cardiff will perform the molecular testing. The results of a rigorous pre-trial inter-laboratory analytical validation are presented and discussed.\ud \ud Methods Wales Cancer Bank supplied FFPE tumour blocks from 97 mCRC patients with consent for use in further research. Both laboratories processed each sample according to an agreed definitive FOCUS4 laboratory protocol, reporting results directly to the MRC Trial Management Group for independent cross-referencing.\ud \ud Results Pyrosequencing analysis of mutation status at KRAS codons12/13/61/146, NRAS codons12/13/61, BRAF codon600 and PIK3CA codons542/545/546/1047, generated highly concordant results. Two samples gave discrepant results; in one a PIK3CA mutation was detected only in Leeds, and in the other, a PIK3CA mutation was only detected in Cardiff. pTEN and mismatch repair (MMR) protein expression was assessed by immunohistochemistry (IHC) resulting in 6/97 discordant results for pTEN and 5/388 for MMR, resolved upon joint review. Tumour heterogeneity was likely responsible for pyrosequencing discrepancies. The presence of signet-ring cells, necrosis, mucin, edge-effects and over-counterstaining influenced IHC discrepancies.\ud \ud Conclusions Pre-trial assay analytical validation is essential to ensure appropriate selection of patients for targeted therapies. This is feasible for both mutation testing and immunohistochemical assays and must be built into the workup of such trials.\ud \ud Trial registration number ISRCTN90061564.

Published
2015

12. Somatic Profiling of the Epidermal Growth Factor Receptor Pathway in Tumors from Patients with Advanced Colorectal Cancer Treated with Chemotherapy ± Cetuximab

Author

Smith, Christopher G., primary, Fisher, David, additional, Claes, Bart, additional, Maughan, Timothy S., additional, Idziaszczyk, Shelley, additional, Peuteman, Gilian, additional, Harris, Rebecca, additional, James, Michelle D., additional, Meade, Angela, additional, Jasani, Bharat, additional, Adams, Richard A., additional, Kenny, Sarah, additional, Kaplan, Richard, additional, Lambrechts, Diether, additional, and Cheadle, Jeremy P., additional

Published
2013
Full Text
View/download PDF

13. Use of epiregulin (EREG) and amphiregulin (AREG) gene expression to predict response to cetuximab (cet) in combination with oxaliplatin (Ox) and 5FU in the first-line treatment of advanced colorectal cancer (aCRC).

Author

Adams, Richard A., primary, Fisher, David, additional, Farragher, Susan, additional, Jasani, Bharat, additional, Smith, Christopher G., additional, James, Michelle D., additional, Cheadle, Jeremy, additional, Nichols, Laura L., additional, Meade, Angela M., additional, Kaplan, Richard S., additional, Wilson, Richard H., additional, Wasan, Harpreet, additional, and Maughan, Tim, additional

Published
2012
Full Text
View/download PDF

14. Epiregulin (EREG) and amphiregulin (AREG) gene expression to predict response to cetuximab therapy in combination with oxaliplatin (Ox) and 5FU in first-line treatment of advanced colorectal cancer (aCRC).

Author

Adams, Richard A., primary, Fisher, David, additional, Farragher, Susan, additional, Scott, Alastair, additional, Smith, Christopher G, additional, James, Michelle D, additional, Cheadle, Jeremy, additional, Nichols, Laura L, additional, Meade, Angela M., additional, Kaplan, Richard S., additional, Wilson, Richard H., additional, Wasan, Harpreet S, additional, and Maughan, Tim, additional

Published
2012
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results